Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
PERFORMANCE II: Two-Year Outcomes
Author(s): William Gray Added: 3 weeks ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego… View more

Vascular Disease and Surgery
ACC 25: Optimizing DAPT Duration
Author(s): Hyo-Soo Kim Added: 1 month ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR… View more

Anticoagulation

Intervention
EuroPCR 24: The ABILITY Study
Author(s): Roxana Mehran Added: 12 months ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary… View more

Intervention
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 1 year ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 9 months ago

Anticoagulation
Prognostic Utility of the ABCD-GENE Score in Asian ACS Patients
Author(s): Cheng Keat Tan , David Bin-Chia Wu , Seh Yi Joseph Tan , et al Added: 1 year ago

Anticoagulation

MI/ACS
Sex Difference in Relative Survival Following PCI
Author(s): Jin-Ho Choi , Jung-Min Choi , Ki-Hong Choi , et al Added: 7 months ago

Demographic

Vascular Disease and Surgery
Mechanisms of Coronary Artery Spasm
Author(s): Kensuke Nishimiya , Jun Takahashi , Kazuma Oyama , et al Added: 1 year ago

Prevention & Chronic Conditions
The XLIMIT Trial: XLIMUS® DES Shows Non-Inferiority to Synergy™ DES
Author(s): Luca Testa Added: 11 months ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9… View more

Intervention